Hypothesis

Pairing inducible OSK expression with transient, low‑effort modulation of DNA methylation pathways—specifically brief DNMT1 inhibition or TET activation—will produce a synergistic epigenetic reset that achieves greater rejuvenation per unit OSK exposure. Circulating cell‑free DNA (cfDNA) methylation age, measured weekly, will serve as a real‑time biomarker to adapt OSK pulse frequency and duration, keeping proliferation markers low and avoiding oncogenic transformation.

Mechanistic Rationale

OSK recruits histone demethylases and chromatin remodelers that erase age‑associated marks, but without c‑Myc it relies on passive dilution during DNA replication for full demethylation. DNMT1 activity during S‑phase remethylates newly synthesized CpGs, counteracting OSK‑driven loss. A short, sub‑toxic pulse of a DNMT1 inhibitor (e.g., 5‑azacytidine at 0.1 mg/kg) reduces this remethylation, allowing OSK‑initiated hypomethylation to persist. Simultaneously, vitamin C boosts TET‑mediated oxidation of 5mC to 5hmC, facilitating active demethylation and stabilizing the open chromatin state induced by OSK. Together, these interventions lower the threshold of OSK expression needed for epigenetic age reversal, thereby reducing the window of proliferative signaling that poses tumorigenic risk.

Predictions

1. In aged mice, OSK + low‑dose DNMT1i will yield a ≥30 % greater reduction in liver and brain Horvath‑clock age than OSK alone at matched doxycycline exposure.
2. cfDNA methylation age will correlate tightly (r > 0.8) with tissue‑specific epigenetic age changes across liver, brain, and blood, and will predict the optimal interval between OSK pulses.
3. Groups receiving OSK + DNMT1i will show no significant increase in Ki‑67 or BrdU incorporation above baseline, whereas OSK‑only groups will exhibit transient proliferative spikes after each pulse.
4. Long‑term (6‑month) follow‑up will reveal no increase in lymphoma or hepatocellular carcinoma incidence in the combination arm, while OSK‑only arms retain a low but measurable risk.

Experimental Design

• Mouse cohorts: 20‑month‑old C57BL/6J males, n = 15 per group. Groups: (1) control (no doxycycline), (2) OSK inducible (doxycycline 2 mg/mL in drinking water, 5 days on/2 days off), (3) OSK + low‑dose DNMT1i (same OSK schedule plus 5‑azacytidine 0.1 mg/kg i.p. on doxycycline days), (4) OSK + vitamin C (1 g/L in drinking water continuously).
• Readouts: cfDNA extracted from plasma weekly; methylation age calculated using a mouse Horvath‑clock CpG set. Tissue samples (liver, hippocampus, skin) collected at weeks 4, 8, 12 for bulk methylation arrays and histological Ki‑67/BrdU staining. Serum cytokines and liver function tests monitored for toxicity.
• Adaptive arm: In a subset of OSK‑only mice, doxycycline dosing is adjusted each week based on the prior week’s cfDNA age change (increase dose if age reduction <5 %, decrease if >15 %). This arm tests whether biomarker‑guided titration can match or exceed the fixed‑schedule outcomes.
• Safety endpoint: Palpable tumors and necropsy‑confirmed neoplasia assessed at 6 months.

Potential Pitfalls and Mitigations

DNMT1 inhibition at higher doses causes global hypomethylation and genomic instability; we limit exposure to a single low dose per OSK pulse and monitor for DNA damage (γH2AX). cfDNA may not fully mirror methylation dynamics in non‑dividing tissues; we will validate correlations in each harvested organ. Species differences in OSK chromatin binding could affect translatability; we include human keratinocyte cultures treated with OSK ± DNMT1i to confirm synergistic demethylation before murine work.

Impact

If validated, this framework converts OSK‑based rejuvenation from a static dosing regimen into a precision medicine strategy. By using an accessible, dynamic biomarker to titrate both reprogramming factors and epigenetic modifiers, we maximize therapeutic benefit while tightly controlling proliferative risk—addressing the foremost safety concern that has slowed clinical adoption.